[8-K] Gyre Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Gyre Therapeutics, Inc. filed a Form 8-K reporting that on September 10, 2025 the company made an updated corporate presentation available on its website and filed that presentation as Exhibit 99.1 to the report. The filing notes the exhibit is dated September 2025 and that the report was signed by Ping Zhang, Executive Chairman and Interim Chief Executive Officer. The 8-K does not include financial results, transaction details, or other operational disclosures; it solely documents the availability and filing of the corporate presentation.

Insights

Corporate Communications Specialist

TL;DR: Routine disclosure: company refreshed its investor presentation and filed it as an exhibit to keep investors informed.

This filing is a standard investor-relations update rather than a material operational or financial disclosure. Making a corporate presentation publicly available and filing it as Exhibit 99.1 ensures compliance with disclosure practices and helps maintain transparency for current and prospective investors. Because the filing contains no financial metrics, forecasts, or deal terms, it is unlikely to be market-moving by itself but can provide updated messaging and strategic context if the presentation includes new program or pipeline detail.

Securities Compliance Analyst

TL;DR: Non-material filing from a regulatory compliance perspective; documents an updated presentation was posted and filed.

From a compliance viewpoint, the 8-K properly attaches the presentation as Exhibit 99.1 and identifies the signer. The report references standard provisions for communications and clarifies no additional exhibits (such as financial statements) were included. Absent substantive operational or financial information, this disclosure meets routine reporting expectations and should be treated as informational rather than material.

false0001124105NASDAQ00011241052025-09-102025-09-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 10, 2025

Gyre Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	000-51173	56-2020050
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

12770 High Bluff Drive Suite 150 San Diego, CA		92130
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (858) 567-7770

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		GYRE		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On September 10, 2025, Gyre Therapeutics, Inc. (the “Company”) made available an updated corporate presentation on the Company’s website. A copy of the corporate presentation is filed herewith as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

 EXHIBIT INDEX

Exhibit No.	Description
99.1	Corporate Presentation, dated September 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	GYRE THERAPEUTICS, INC.
Date: September 10, 2025	By:	/s/ Ping Zhang
	Name:	Ping Zhang
	Title:	Executive Chairman and Interim Chief Executive Officer

FAQ

What did Gyre Therapeutics (GYRE) disclose in this Form 8-K?

The company disclosed that it made an updated corporate presentation available on its website and filed that presentation as Exhibit 99.1 dated September 2025.

Does the 8-K include financial results or transaction details for GYRE?

No. The filing contains no financial statements, earnings data, or transaction disclosures; it only documents the availability and filing of the presentation.

Who signed the Form 8-K for Gyre Therapeutics?

The Form 8-K was signed by Ping Zhang, Executive Chairman and Interim Chief Executive Officer.

When was the updated corporate presentation filed?

The presentation was made available and filed on September 10, 2025 and is dated September 2025.

Where can investors find the updated presentation referenced in the 8-K?

The presentation was made available on the company's website and is also filed as Exhibit 99.1 to the Form 8-K.